Research & Development: Page 42
-
PharmaVoice Team/PharmaVoice
Transformation: Ready, Set, Agile
According to McKinsey, companies that have enterprise agility share some commonalities: a North Star-mentality, in other words an overarching customer strategy; a scalable team structure; a rapid decision-making mentality; a dynamic people model that ignites passion; and a willing adoption of nex...
By PharmaVoice Team • Feb. 1, 2019 -
PharmaVoice Team/PharmaVoice
Red Zone: Disruptive Innovation: Questions for the C-Suite
It is not the strongest of the species that survives, nor is it the most intelligent. It is the one that is most adaptable to change. Whether a direct quote from Charles Darwin or a summary of his writings, this statement is perhaps the most profound scientific explanation of life itself, in all ...
By Srini Shankar • Feb. 1, 2019 -
Explore the Trendline➔
Getty Images
TrendlineOncology R&D
Cancer research remains a prime focus for the industry and often leads to pharma’s most impactful breakthroughs.
By PharmaVoice staff -
PharmaVoice Team/PharmaVoice
Letter from the Editor
Artificial Intelligence Happy New Year. As we enter 2019, we take note of one of the major trends expected to impact all aspects of the life-sciences industry: artificial intelligence. In 2019, according to Forrester, AI solutions will continue to spread across the healthcare continuum thanks to ...
By Taren Grom • Jan. 1, 2019 -
PharmaVoice Team/PharmaVoice
Upfront
Medicinal Theater BioMarin Pharmaceutical and Believe Ltd. sponsored a first-of-its-kind theatrical production for teenagers with hemophilia. The musical, Hemophilia: The Musical, took place at New World Stages on Nov. 12, 2018. Before the performance, students participated in the Breaking Throug...
By PharmaVoice Team • Jan. 1, 2019 -
PharmaVoice Team/PharmaVoice
HealthTech
Payers Use Healthtech to Improve Patient Outcomes, Lower Costs Trend Watch: Healthtech Mobile App Market Continues To Grow Payers Offer Free Wearables UnitedHealthcare, Aetna, and John Hancock have all implemented programs that offer free Apple Watches to customers, if they exercise daily. The la...
By PharmaVoice Team • Jan. 1, 2019 -
PharmaVoice Team/PharmaVoice
Artificial Intelligence
Artificial Intelligence Key to Improving Healthcare Quality, Reducing Costs Trend Watch: AI Implications for Healthcare are Widespread Artificial Intelligence (AI) is key to building a better healthcare future, according to a recent survey of 500 U.S. healthcare leaders on their attitudes and usa...
By PharmaVoice Team • Jan. 1, 2019 -
PharmaVoice Team/PharmaVoice
Innovator's Corner
Modifying the Immune Response in Celiac Leslie Williams, CEO of ImmusanT, discusses the company’s research for developing a disease-modifying therapeutic for patients with celiac disease. Celiac disease is often misunderstood as a lifestyle disease. Unmanaged, celiac can result in chronic anemia,...
By Leslie Williams • Jan. 1, 2019 -
PharmaVoice Team/PharmaVoice
Artificial Intelligence: Molecule to Market
The adoption of artificial intelligence (AI) is rapidly taking hold across global businesses, including the life-sciences industry. AI is typically defined as the ability of a machine to perform cognitive functions associated with human minds, such as perceiving, reasoning, learning, and problem ...
By PharmaVoice Team • Jan. 1, 2019 -
PharmaVoice Team/PharmaVoice
The Coming Wave of Cannabis-based Medicines
Cannabis has remained a source of controversy — from debates on its medicinal value and legalization to concerns about dependency. Cannabis is a hot-button issue among patients, healthcare practitioners, and policymakers. But that is changing. In fact, 32 states and Washington, D.C., now allow ma...
By Denise Myshko • Jan. 1, 2019 -
PharmaVoice Team/PharmaVoice
Letter from the Editor
The year ahead… As we come to the end of 2018, it’s important to pause and reflect on not just where we’ve been, but where we are going as an industry. In 2018, we saw continuing uncertainty in terms of the Affordable Care Act. We welcomed Alex Azar as the new Secretary of Health and Human Servic...
By Taren Grom • Nov. 15, 2018 -
PharmaVoice Team/PharmaVoice
Upfront
Johnson & Johnson Announces 10-year Initiative to Help End Tuberculosis Johnson & Johnson has announced a comprehensive 10-year initiative in support of the United Nations’ Sustainable Development Goal target of ending the TB pandemic by 2030. With the goal of saving an estimated 1.8 mill...
By PharmaVoice Team • Nov. 15, 2018 -
PharmaVoice Team/PharmaVoice
HealthTech
Nanomedicine Zeros In On Triple Negative Breast Cancer Cells Trend Watch: From Breast Cancer to Asthma, Healthtech Tools Develop Care Solutions Researchers at George Washington University have shown that a technique of delivering a chemotherapy agent within specially designed nanoparticles can be...
By PharmaVoice Team • Nov. 15, 2018 -
PharmaVoice Team/PharmaVoice
2019 Trend Tracking
In this special 2019 Year in Preview issue, more than 100 PharmaVOICE thought leaders address 10 trends that are expected to be part of the changing landscape in the year ahead. These areas of focus cover a variety of disparate topics that range from molecule to market in keeping with our publish...
By Taren Grom • Nov. 15, 2018 -
PharmaVoice Team/PharmaVoice
Looking Forward To
AI Adoption Richard Davies VP, Solution Expert, CluePoints The application of artificial intelligence and machine learning within the R&D process to guide disparate stakeholders through the planning and execution of clinical trials through targeted risk management is both a current capability...
By Taren Grom • Nov. 15, 2018 -
PharmaVoice Team/PharmaVoice
Trend: 3D and Bioprinting
The bioprinting field continues to grow and mature. With the evolution of the technology, experts believe even broader applications are on the horizon, providing patients with fully functioning cells — and even organs — that have been created through bioprinting processes. “All of us can envision...
By Denise Myshko • Nov. 15, 2018 -
PharmaVoice Team/PharmaVoice
Trend: Advanced Diagnostics and Precision Medicine
Healthcare is moving increasingly toward personalized approaches — tailoring treatment based on each patient’s unique disease. Precision medicine is well-established in oncology, with many cancers now characterized by their unique genomic alterations. In the past few years, the Food and Drug Admi...
By PharmaVoice Team • Nov. 15, 2018 -
PharmaVoice Team/PharmaVoice
Trend: Rare Disease Innovation
It’s been almost 120 years since the word gene was coined. Today, researchers are well on their way to manipulating genes to treat diseases. With only about 400 approved treatments for more than 7,000 rare diseases — 80% of which are caused by gene mutations — scientific advances are enabling gen...
By PharmaVoice Team • Nov. 15, 2018 -
PharmaVoice Team/PharmaVoice
Trend: R&D Modeling and Simulation
The Food and Drug Administration for several years has been advocating for the use of computer modeling and simulation as a way to accelerate access to new therapies. First proposed by the agency in 2011 as part of its Critical Path Initiative, modeling and simulation are gaining traction, with t...
By Denise Myshko • Nov. 15, 2018 -
PharmaVoice Team/PharmaVoice
Speak Out
Looking to Simplify Your Safety Notifications Process? Consider a Cross-Trial SaaS Solution Why new centralized SaaS solutions make more sense than ever before A traffic-light is out of service during rush hour in a busy city intersection. To prevent accidents, a police officer is there directing...
By Brian Fisher • Nov. 15, 2018 -
PharmaVoice Team/PharmaVoice
Letter from the Editor
Innovation meets the market There are 977 clinical trials under way for products that use regenerative medicine technology. There are more than 150 gene therapy drugs in Phase I, II and III clinical trials in progress as rare disease research enters into a new era of patient-focused innovation. A...
By Taren Grom • Oct. 1, 2018 -
PharmaVoice Team/PharmaVoice
Innovator's Corner
Discovered by AI Dr. Vimal Mehta, CEO of BioXcel Therapeutics, talks about the company’s clinical candidates identified through an artificial intelligence and machine-learning platform. BioXcel Therapeutics is showing that investments in artificial intelligence (AI) and machine learning can pay o...
By Dr. Vimal Mehta • Oct. 1, 2018 -
PharmaVoice Team/PharmaVoice
Agencies Pay It Forward
In an open letter to CEOs earlier this year, BlackRock CEO and financial wizard Larry Fink outlined the need for companies to start focusing on the world outside their walls and find a way to serve a larger societal purpose. His thought process is that while focusing on building revenue, companie...
By PharmaVoice Team • Oct. 1, 2018 -
PharmaVoice Team/PharmaVoice
Trial Sites and Patient Diversity
Having a diverse patient population in clinical trials is important because medicines affect people differently based on age, sex, and race. Biologic, genetic, and even cultural differences between patients can impact how a treatment will actually work in practice. Industry experts say the racial...
By Denise Myshko • Oct. 1, 2018 -
PharmaVoice Team/PharmaVoice
Red Zone: Avoid Enrollment Pitfalls by Engaging with Best-Fit Sites
Perhaps the single most important consideration in selecting a site is whether it can make its enrollment. Many don’t; in fact, 20-25 percent of all clinical studies close because they fail to meet enrollment targets.1 For decades, sponsors have found their “best fit" sites and returned to them f...
By WCG Clinical Services • Oct. 1, 2018 -
PharmaVoice Team/PharmaVoice
Letter from the Editor
In the People Business According to PhRMA, 74% of the medicines in clinical development are potentially first-in-class medicines, meaning they represent a possible new pharmacological class for treating a medical condition. Furthermore, PhRMA reports that there are 822 projects, defined as unique...
By Taren Grom • Sept. 1, 2018
Previous
